CPHI [CHINA PHARMAS,] DEF 14C: (Original Filing)

[Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 3)]

By | 2016-03-03T20:24:46+00:00 May 5th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] DEF 14C: Payment of Filing Fee (Check the appropriate box):

[Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 3)]

By | 2016-03-03T20:25:42+00:00 May 5th, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CXDC [China XD Plastics Co] 10-K/A: EXPLANATORY NOTE —

[EXPLANATORY NOTE —] [I, Jie Han, certify that: 1. I have reviewed this annual report on Form 10-K/A of China XD Plastics Company Limited; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [Certification of Principal Financial Officer I, Taylor Zhang, certify that: 1. I have reviewed this annual report on Form 10-K/A of China XD Plastics Company Limited; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Taylor Zhang Principal Financial and Accounting Officer] [Response Staff Comment 3. http://pcaobs.org/Standards/QandA/QA_Adjustments.pdf Response The Company acknowledges that: · The Company is responsible for the adequacy and accuracy of the disclosure in the filing; · Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and ·]

By | 2016-03-25T18:39:50+00:00 May 5th, 2010|Categories: Chinese Stocks, CXDC, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] DEF 14C: (Original Filing)

[SCHEDULE 14C INFORMATION Check the appropriate box: [] Preliminary Information Statement [] [X] Definitive Information Statement CHINA PHARMAS, Payment of Filing Fee (Check the appropriate box): [X] No fee required. [] Feemputed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which transaction applies:]

By | 2016-02-07T23:28:59+00:00 May 5th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] DEF 14C: SCHEDULE 14C INFORMATION Check the appropriate box: []

[SCHEDULE 14C INFORMATION Check the appropriate box: [] Preliminary Information Statement [] [X] Definitive Information Statement CHINA PHARMAS, Payment of Filing Fee (Check the appropriate box): [X] No fee required. [] Feemputed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which transaction applies:]

By | 2016-02-07T23:29:33+00:00 May 5th, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar